"Charles Vista, LLC is pleased with the successful raise for DelMar's enduring clinical trials to treat a devastating form of cancer.
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced the completion of a $10.5 million oversubscribed offering in which Charles Vista, LLC was the sole lead underwriter. The money raised will help advance the clinical trials of DelMar's pharmaceuticals, including VAL-083, for treating ref...
